Open access
Open access
Powered by Google Translator Translator

Covid-19

Consensus Statement: Successfully implementing digital health to ensure future global health security during pandemics.

25 Feb, 2022 | 11:34h | UTC

Successfully Implementing Digital Health to Ensure Future Global Health Security During Pandemics: A Consensus Statement – JAMA Network Open

 


At least 5 million children have lost a parent or caregiver due to COVID-19 since March 2020, updated figures suggest.

25 Feb, 2022 | 11:32h | UTC

News Release:  At least 5 million children have lost a parent or caregiver due to COVID-19 since March 2020, updated figures suggest – The Lancet

Original Study: Global, regional, and national minimum estimates of children affected by COVID-19-associated orphanhood and caregiver death, by age and family circumstance up to Oct 31, 2021: an updated modelling study – The Lancet Child & Adolescent Health

Commentaries:

Integrative approaches required to support children affected by COVID-19 – The Lancet Child & Adolescent Health

Millions of children worldwide have lost a parent or caregiver to COVID-19: “The hidden pandemic” – CBS News

Related:

More than 1.5 million children lost a primary or secondary caregiver due to the COVID-19 pandemic.

Covid-19 Has Created Thousands Of Newly Single Parents And Orphans

 

Commentary on Twitter (thread – click for more)

 


Study suggests multisystem inflammatory syndrome in children (MIS-C) is rare among vaccinated teens.

25 Feb, 2022 | 11:29h | UTC

Reported cases of multisystem inflammatory syndrome in children aged 12–20 years in the USA who received a COVID-19 vaccine, December, 2020, through August, 2021: a surveillance investigation – The Lancet Child & Adolescent Health

Commentaries:

When vaccine adverse event reporting generates hope, not fear – The Lancet Child & Adolescent Health

MIS-C rare in COVID-vaccinated teens, study finds – CIDRAP

Vaccination Greatly Reduces Odds of MIS-C in Teens Who Get COVID – HealthDay

 

Commentary on Twitter

 


Editorial: Addressing vaccine inequity — Covid-19 vaccines as a global public good.

24 Feb, 2022 | 10:41h | UTC

Addressing Vaccine Inequity — Covid-19 Vaccines as a Global Public Good – New England Journal of Medicine

 


Previous population immunity and Covid-19 severity with Omicron variant in South Africa.

24 Feb, 2022 | 10:43h | UTC

Population Immunity and Covid-19 Severity with Omicron Variant in South Africa – New England Journal of Medicine

Audio Interview: Understanding the Omicron Variant of SARS-CoV-2

 

Commentary on Twitter

 


RCT: Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine.

24 Feb, 2022 | 10:20h | UTC

Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial – Annals of Rheumatic Diseases

Commentary: Suspend Methotrexate for RA Patients Getting COVID Vax?— It’s not a simple choice, Brazilian study suggests (free registration required)

 


[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.

24 Feb, 2022 | 10:30h | UTC

Fourth dose of COVID vaccine offers only slight boost against Omicron infection – Nature

Original Study: 4th Dose COVID mRNA Vaccines’ Immunogenicity & Efficacy Against Omicron VOC – medRxiv

 


Two large populational-based studies find a slightly increased risk of thrombotic events following AstraZeneca COVID-19 vaccination.

24 Feb, 2022 | 10:23h | UTC

Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England – PLOS Medicine

See also: First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: A pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales – PLOS Medicine

Commentaries:

Two studies find only small elevated risk of blood clots following AstraZeneca COVID-19 vaccination – PLOS

Two Large Studies Affirm Rare Thrombosis Risk With ChAdOx1 COVID-19 Vax – TCTMD

 


Meta-analysis finds low risk of a second allergic reaction to SARS-CoV-2 mRNA vaccines in patients with an allergic reaction with the first dose.

22 Feb, 2022 | 10:05h | UTC

Risk of Second Allergic Reaction to SARS-CoV-2 Vaccines: A Systematic Review and Meta-analysis – JAMA Internal Medicine

 

Commentary on Twitter

 


UK unveils game plan for ‘living with COVID’.

22 Feb, 2022 | 09:56h | UTC

UK unveils game plan for ‘living with COVID’ – CIDRAP

See also:

All you need to know about the end of Covid rules in England – The Guardian

‘Living with Covid’ strategy could do more harm than good, say businesses and unions – The Guardian

 


Opinion by Dr. Eric Topol | Why one-shot after a Covid-19 infection should suffice to be considered fully-vaxxed.

22 Feb, 2022 | 10:07h | UTC

Why one-shot after a Covid-19 infection should suffice to be considered fully-vaxxed – The Guardian

 

Commentary from the author on Twitter (thread – click for more)

 


Why does the Omicron sub-variant spread faster than the original?

22 Feb, 2022 | 09:55h | UTC

Why does the Omicron sub-variant spread faster than the original? – Nature

Related:

Conflicting reports raise questions about whether any monoclonals work against Omicron’s sister variant.

Covid-19: What do we know about omicron sublineages?

We regret to inform you that we are now discussing subvariants – Vox

Sudden rise of more transmissible form of Omicron catches scientists by surprise.

Omicron’s sister variant spreads faster. So why did the one we call Omicron hit first?

[Preprint] Study suggests SARS-CoV-2 Omicron subvariants BA.2 is even more transmissible than the original variant.

BA.2 is like Omicron’s sister. Here’s what we know about it so far – The Conversation

 


[Preprint] A large-scale observational study in Chile found CoronaVac (an inactivated SARS-CoV-2 vaccine) was associated with an effectiveness of 74.5% against infection, 91.0% against hospitalization, and 93.8% against ICU admission in children aged 6 to 16 years.

22 Feb, 2022 | 09:58h | UTC

Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Children and Adolescents: A Large-Scale Observational Study – Preprints with The Lancet

Commentary: Full schedule of CoronaVac vaccine shown to be highly effective in children – News Medical

 


ESCMID rapid guidelines for assessment and management of long COVID.

21 Feb, 2022 | 09:31h | UTC

ESCMID rapid guidelines for assessment and management of long COVID – Clinical Microbiology and Infection

Related:

ERS statement on Long COVID-19 follow-up.

Proposed subtypes of long-Covid and their respective potential therapies.

EuGMS Guidance: Management of post-acute COVID-19 patients in geriatric rehabilitation.

Addressing Post-COVID Symptoms: A Guide for Primary Care Physicians.

Global surveillance, research, and collaboration needed to improve understanding and management of long COVID.

Provocative study suggests that persistent physical symptoms after COVID-19 infection may be associated more with the belief in having been infected with SARS-CoV-2 than with having laboratory-confirmed COVID-19 infection.

Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’.

Systematic Review: Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection.

WHO Consensus: A clinical case definition of post COVID-19 condition (Long Covid).

Characterizing long COVID: a living systematic review.

Long Covid – The illness narratives.

New guidelines to help doctors manage long COVID patients published.

M-A: More than 50 long-term effects of COVID-19. (several articles on the subject)

 


RCT: In patients with mild to moderate Covid-19 and comorbidities, treatment with Ivermectin did not reduce the risk of disease progression.

21 Feb, 2022 | 09:34h | UTC

Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities: The I-TECH Randomized Clinical Trial – JAMA Internal Medicine

Commentaries:

Ivermectin doesn’t prevent severe disease from Covid-19, new study finds – CNN

Ivermectin futile for mild to moderate COVID-19, study finds – CIDRAP

Related:

Case Series: Toxic effects from ivermectin use associated with prevention and treatment of Covid-19.

Long-term consequences of the misuse of ivermectin data.

Ivermectin: How false science created a Covid ‘miracle’ drug.

Fraudulent ivermectin studies open up new battleground between science and misinformation.

The lesson of ivermectin: meta-analyses based on summary data alone are inherently unreliable.

Ivermectin: Cochrane’s most talked about review so far, ever. Why?

Flawed ivermectin preprint highlights challenges of COVID drug studies.

Systematic review: no evidence to support the use of Ivermectin for treating or preventing COVID-19.

Why was a major study on ivermectin for covid-19 just retracted?

RCT: Ivermectin does not prevent hospitalizations in patients with COVID-19.

Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials – “IVM did not reduce all-cause mortality, length of stay or viral clearance in RCTs in COVID-19 patients with mostly mild disease”.

Ivermectin is the new hydroxychloroquine, take 2 – “Ivermectin shouldn’t be used to treat COVID-19 outside of the context of a well-designed clinical trial”.

Therapeutics and COVID-19 | WHO guideline update advises Ivermectin should only be used to treat COVID-19 within clinical trials

RCT: Ivermectin does not improve time to resolution of symptoms among adults with mild COVID-19

 


Review | Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus.

21 Feb, 2022 | 09:30h | UTC

Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus – European Heart Journal

News Release: Review highlights impact of Long COVID on cardiovascular system – University of Oxford

Related:

The pathogenesis and long-term consequences of Covid-19 cardiac injury: state-of-the-art review.

COVID-19 infections increase risk of heart conditions up to a year later, study finds.

 


Perspective | Is it time to live with COVID-19? Some scientists warn of ‘endemic delusion’.

21 Feb, 2022 | 09:28h | UTC

Is it time to live with COVID-19? Some scientists warn of ‘endemic delusion’ – Science

 


Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis.

21 Feb, 2022 | 09:33h | UTC

Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis – International Journal of Infectious Diseases

 


Cohort Study: Risks of mental health outcomes in people with covid-19.

18 Feb, 2022 | 10:02h | UTC

Risks of mental health outcomes in people with covid-19: cohort study – The BMJ

Editorial: Mental health after covid-19 – The BMJ

News release: Study suggests increased risk of mental health disorders after COVID-19 infection – BMJ

Commentaries:

Mental health in people with covid-19 – The BMJ

Large study reveals clearer links between COVID-19, mental health risks – CIDRAP

 


Another study suggests a lower risk of hospitalization and death from infection with SARS-CoV-2 Omicron variant vs. Delta.

18 Feb, 2022 | 10:01h | UTC

Estimates of SARS-CoV-2 Omicron Variant Severity in Ontario, Canada – JAMA

 


The pathogenesis and long-term consequences of Covid-19 cardiac injury: state-of-the-art review.

18 Feb, 2022 | 09:56h | UTC

The Pathogenesis and Long-Term Consequences of COVID-19 Cardiac Injury: State-of-the-Art Review – JACC: Basic to Translational Science

Related: COVID-19 infections increase risk of heart conditions up to a year later, study finds.

 


WHO Interim Guidance: Contact tracing and quarantine in the context of the Omicron SARS-CoV-2 variant.

18 Feb, 2022 | 09:59h | UTC

Contact tracing and quarantine in the context of the Omicron SARS-CoV-2 variant: interim guidance – World Health Organization

 

Commentary on Twitter (thread – click for more)

 


Opinion | Coronaviruses are ‘clever’: Evolutionary scenarios for the future of SARS-CoV-2.

18 Feb, 2022 | 09:54h | UTC

Coronaviruses are ‘clever’: Evolutionary scenarios for the future of SARS-CoV-2 – STAT

 


Perspective: We’re entering the control phase of the pandemic.

18 Feb, 2022 | 08:49h | UTC

We’re Entering the Control Phase of the Pandemic – The Atlantic

 


Cohort study: Protection against SARS-CoV-2 after Covid-19 vaccination lasts longer in patients with previous infection.

17 Feb, 2022 | 10:11h | UTC

Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection – New England Journal of Medicine

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.